Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · Real-Time Price · USD
27.11
-0.43 (-1.56%)
Aug 21, 2026, 4:00 PM EDT - Market closed
Collegium Pharmaceutical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 808.21 | 780.57 | 631.45 | 566.77 | 463.93 | 276.87 | |
Revenue Growth | 14.31% | 23.61% | 11.41% | 22.17% | 67.56% | -10.69% |
Cost of Revenue | 85.27 | 86.93 | 83.53 | 94.84 | 118.19 | 59.07 |
Gross Profit | 722.93 | 693.64 | 547.92 | 471.93 | 345.74 | 217.8 |
Selling, General & Admin | 321.91 | 278.66 | 182.98 | 150.71 | 172.19 | 118.96 |
Research & Development | - | - | - | - | 3.98 | 9.45 |
Amortization of Goodwill & Intangibles | 229.37 | 221.89 | 165.3 | 145.76 | 131.47 | 67.18 |
Operating Expenses | 551.28 | 500.55 | 348.29 | 296.47 | 307.64 | 195.59 |
Operating Income | 171.65 | 193.09 | 199.63 | 175.46 | 38.11 | 22.21 |
Interest Expense | -76.44 | -82.31 | -73.97 | -83.34 | -63.21 | -21.01 |
Interest & Investment Income | 12.68 | 11.29 | 13.98 | 15.62 | 1.05 | 0.01 |
EBT Excluding Unusual Items | 107.89 | 122.07 | 139.63 | 107.74 | -24.06 | 1.2 |
Merger & Restructuring Charges | -9.23 | -9.61 | -29.6 | - | - | -4.58 |
Asset Writedown | -0.58 | -0.58 | - | - | -4.79 | - |
Legal Settlements | -3.06 | -3.06 | - | -8.5 | - | - |
Other Unusual Items | -17.35 | -16.21 | -11.47 | -23.5 | - | - |
Pretax Income | 77.68 | 92.62 | 98.57 | 75.73 | -28.85 | -3.37 |
Income Tax Expense | 29.77 | 29.75 | 29.38 | 27.58 | -3.85 | -74.89 |
Net Income | 47.92 | 62.87 | 69.19 | 48.16 | -25 | 71.52 |
Net Income to Common | 47.92 | 62.87 | 69.19 | 48.16 | -25 | 71.52 |
Net Income Growth | 32.10% | -9.13% | 43.68% | - | - | 167.33% |
Shares Outstanding (Basic) | 32 | 32 | 32 | 34 | 34 | 35 |
Shares Outstanding (Diluted) | 36 | 40 | 40 | 42 | 34 | 41 |
Shares Change | -9.07% | -1.79% | -3.26% | 23.53% | -17.58% | 16.77% |
EPS (Basic) | 1.50 | 1.98 | 2.14 | 1.43 | -0.74 | 2.05 |
EPS (Diluted) | 1.41 | 1.73 | 1.86 | 1.29 | -0.74 | 1.86 |
EPS Growth | 32.73% | -6.56% | 43.56% | - | - | 144.25% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 328.28 | 327.58 | 203.33 | 274.29 | 122.61 | 101.61 |
Free Cash Flow Per Share | 9.07 | 8.25 | 5.03 | 6.56 | 3.62 | 2.48 |
Gross Margin | 89.45% | 88.86% | 86.77% | 83.27% | 74.52% | 78.66% |
Operating Margin | 21.24% | 24.74% | 31.61% | 30.96% | 8.21% | 8.02% |
Profit Margin | 5.93% | 8.05% | 10.96% | 8.50% | -5.39% | 25.83% |
Free Cash Flow Margin | 40.62% | 41.97% | 32.20% | 48.39% | 26.43% | 36.70% |
EBITDA | 405.26 | 419.16 | 368.79 | 324.72 | 172.26 | 91.12 |
EBITDA Margin | 50.14% | 53.70% | 58.40% | 57.29% | 37.13% | 32.91% |
D&A For EBITDA | 233.6 | 226.07 | 169.16 | 149.26 | 134.15 | 68.92 |
EBIT | 171.65 | 193.09 | 199.63 | 175.46 | 38.11 | 22.21 |
EBIT Margin | 21.24% | 24.74% | 31.61% | 30.96% | 8.21% | 8.02% |
Effective Tax Rate | 38.32% | 32.12% | 29.80% | 36.41% | - | - |
Advertising Expenses | - | 27.78 | 10.66 | 7.41 | 11.74 | 4.19 |